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 SARS-COV-2 is structurally similar to SARS-COV 
 The mechanism of SARS-COV-2 in the host cell may be comparable to 
SARS-COV 
 SARS-CoV-2 invade the immune and nervous system 
 There is an urgent need for novel treatment options for COVID-19 
 Indian medicinal plants are likely to be potential drugs for the treatment of 
COVID-19 
 





The novel Coronavirus disease 2019 (COVID-19) is caused by SARS-CoV-2, which 2 
is the causative agent of a potentially fatal disease that is of great global public health 3 
concern. The outbreak of COVID-19 is wreaking havoc worldwide due to inadequate 4 
risk assessment regarding the urgency of the situation. The COVID-19 pandemic has 5 
entered a dangerous new phase. When compared with SARS and MERS, COVID-19 6 
has spread more rapidly, due to increased globalization and adaptation of the virus in 7 
every environment. Slowing the spread of the COVID-19 cases will significantly 8 
reduce the strain on the healthcare system of the country by limiting the number of 9 
people who are severely sick by COVID-19 and need hospital care. Hence, the recent 10 
outburst of COVID-19 highlights an urgent need for therapeutics targeting SARS-11 
CoV-2. Here, we have discussed the structure of virus; varying symptoms among 12 
COVID-19, SARS, MERS and common flu; the probable mechanism behind the 13 
infection and its immune response. Further, the current treatment options, drugs 14 
available, ongoing trials and recent diagnostics for COVID-19 have been discussed. 15 
We suggest traditional Indian medicinal plants as possible novel therapeutic 16 
approaches, exclusively targeting SARS-CoV-2 and its pathways. 17 
Keywords: Coronavirus disease 2019 (COVID-19); SARS-CoV-2; Mechanism of 18 
action; Therapeutic approach; Indian traditional medicine.    19 
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 21 
ACE2: Angiotensin-Converting Enzyme 2; ACE2-Fc: Angiotensin Converting 22 
Enzyme 2 Fc; ADAM17: ADAM metallopeptidase domain 17; ARDS: Acute 23 
respiratory distress syndrome; ASC: Apoptosis-associated speck-like protein 24 
containing a CARD; CNS: Central Nervous System; COVID-19: Coronavirus disease 25 
2019; ER: Endoplasmic reticulum; ExoN: exoribonuclease; FDA: Food and Drug 26 
Administration; FP: internal fusion protein; HCoV: Human coronavirus; HIV: Human 27 
immunodeficiency virus; JAK-STAT: Janus kinase/signal transducer and activator of 28 
transcription; JNK: c-Jun N- terminal kinase; MCP-1: Monocyte chemoattractant 29 
protein-1; MERS: Middle East respiratory syndrome; MERS-CoV: Middle East 30 
respiratory syndrome coronavirus; MHV: Mouse hepatitis virus; mRNA: Messenger 31 
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RNA; NF-kB: Nuclear Factor kappa-light-chain-enhancer of activated B-cells; NIH: 32 
National Institutes of Health; NLRP3: Nod-like receptor protein 3; ORF: open reading 33 
frame; PHEIC: Public Health Emergency of International Concern; PHEV: Porcine 34 
Hemagglutinating Encephalomyelitis Virus;  RBD: receptor binding domain; RBM: 35 
receptor binding motif; RCT: randomized controlled treatment; RdRp: RNA 36 
dependent RNA polymerase; RNA: Ribonucleic acid; ROS: Reactive oxygen species; 37 
RTC: replicase-transcriptase complex; SARS: Severe acute respiratory syndrome; 38 
SARS-COV-2: Severe acute respiratory syndrome coronavirus-2; TM: 39 
transmembrane; TMPRSS11a: Transmembrane serine protease 11a; TNFβ: Tumor 40 
necrosis factor β; TRAF3: TNF receptor associated factor 3; TRS: transcriptional 41 
regulatory sequence; WHO: World Health Organization 42 
 43 
1. Introduction 44 
The novel coronavirus disease 2019 (COVID-19), caused by the Severe acute 45 
respiratory syndrome coronavirus-2 (SARS-CoV-2), is in the midst of worldwide 46 
panic and global health concern since December 2019. As of March 26
th
, 2020, the 47 
World Health Organization (WHO) has reported that 4,16,686 and 18,589 death cases 48 
have been confirmed worldwide, and it has spread to 197 countries (WHO, 2020a). 49 
With this emerging battle against this deadly virus, the WHO has strategized to 50 
interrupt human-human contact, isolate patients at early stages, identify and reduce 51 
transmission from the animal source, address crucial mysteries about the virus and 52 
accelerate research, communicate information correctly to the public and minimize 53 
the social and economic impact. At this juncture, it is tremendously vital to 54 
understand the basic mechanism of the virus to develop specific drugs. Currently, it 55 
has been established that SARS-CoV-2 shares sequence homology with the SARS-56 
CoV and a bat coronavirus (Gorbalenya, 2020). Despite its similarity to SARS-CoV, 57 
its transmission efficiency and diagnostic methods are rather different. The 58 
distinguishing factor is probably the nucleotide changes in the spike (S) protein and 59 
its receptor-binding domain (RBD) (Kannan et al., 2020; Coutard et al., 2020; Wan et 60 
al., 2020). Currently, the treatments include Lopinavir/Ritonavir and supportive care, 61 




standpoint, various drugs are being developed at an extremely quick pace and new 63 
targets are being identified every day, and also numerous drugs are also undergoing 64 
clinical trials. Researches are very curious about how to provide the best protection to 65 
the public before a vaccine can be made available (Balachandar et al., 2020). Indian 66 
medicinal herbs are a promising field for treatment of various illnesses (Gomathi et 67 
al., 2020). Ayurveda and Siddha practices originated in India and are still widely used 68 
among the Indian population. By identifying certain phytocompounds, it is possible to 69 
effectively characterize medicinal herbs that could help to alleviate the infection. 70 
Hence, by repurposing the Indian medicinal plants, more innovative treatment options 71 
can be penned down for their role in defeating this viral transmission. At a time of 72 
worldwide anxiety, it is imperative to find long term solutions to prevent the 73 
transmission of such pandemics. So, it’s time for all the citizens to join hands together 74 
to fight against coronavirus by practicing self-hygiene and social distancing 75 
(Balachandar et al., 2020). In this review, the structure, immunological influence, 76 
mechanism of action of the SARS-CoV-2 infection in the human host cell, the 77 
availability of disease-specific drugs, ongoing clinical trials, recent diagnostics and 78 
the potential use of certain Indian medicinal herbs for the effective treatment of 79 
COVID-19 has been discussed. Through this review, we suggest that the Indian 80 
traditional medicinal herbs may be a beneficial step to combat viruses like the SARS-81 
CoV-2. 82 
2. A brief overview of coronavirus 83 
Coronaviruses, having a total of 39 species under the broad realm of 84 
Riboviria, belong to the family Coronaviridae, suborder Cornidovirineae and order 85 
Nidovirales (Gorbalenya et al., 2020). All the SARS-CoV fall under the species 86 




Most of the species under this head are enzootic and only a few of these species infect 88 
humans (Schoeman and Fielding, 2019). Currently, seven human CoVs (HCoVs) 89 
have been confirmed. Specifically, they are named as Human coronavirus NL63 90 
(HCoV-NL63) and Human coronavirus 229E (HCoV-229E), which belong to the 91 
alpha-coronavirus genus; whereas Human coronavirus OC43 (HCoV-OC43), Human 92 
coronavirus (HCoV-HKU1), SARS-CoV, SARS-CoV-2 and Middle East respiratory 93 
syndrome coronavirus (MERS-CoV), belong to the beta-coronavirus genus. HCoV-94 
229E, HCoV-NL63, HCoV-HKU1 and HCoV-OC43 strains of coronavirus cause 95 
mild respiratory diseases in humans. The SARS-CoV-2 is a zoonotic virus that 96 
belongs to the Coronaviridae family that can infect human and several animal species 97 
(Lu et al., 2020). The SARS-CoV-2 belongs to the subgenus Sarbecovirus and mostly 98 
resembles a bat coronavirus, with which it shares 96.2% sequence homology (Chan et 99 
al., 2020a). Currently, it is thought that SARS-CoV-2 has been introduced to human 100 
by an unidentified intermediary animal and then it has spread from human-to-human.  101 
Human coronaviruses are predominantly concomitant with upper respiratory 102 
tract illnesses ranging from mild to moderate including common cold. Most of the 103 
people may be infected with one or more of these viruses at some point in their 104 
lifetime (Killerby et al., 2018). The SARS-CoV and MERS-CoV are the two major 105 
causes of severe pneumonia in human (Song et al., 2019). A comparative analysis of 106 
the symptoms among COVID-19, SARS, MERS and common flu has been explained 107 
(Table.1). The world observed the sudden emergence of COVID-19 in 2019. The 108 
exact origin of the virus, continues to remain as a mystery, to researchers worldwide. 109 
Investigations need to be carried out to pinpoint the exact source of infection. The 110 
WHO, on February 11, 2020, officially named the viral disease COVID-19 (Jiang, et 111 




Committee on Taxonomy of Viruses named the new pathogen as SARS-CoV-2 113 
(Gorbalenya, 2020). The predecessor SARS-CoV first emerged in 2002. During its 114 
course of infection from 2002 to 2003, 774 deaths were recorded out of the 8000+ 115 
infections spread across 37 countries (Peiris et al., 2004). This was closely followed 116 
by the emergence of MERS-CoV at Saudi Arabia in 2012, which caused 858 deaths 117 
among the 2494 known infected cases (Zaki et al., 2012). Similar to its antecedents, 118 
the SARS-CoV-2 appeared in December 2019 from the animal kingdom and spread to 119 
human populations. The COVID-19 is known to show symptoms slowly over an 120 
incubation period of around 2 weeks. During this time the virus replicates in the upper 121 
and lower respiratory tract, forming lesions (Chan et al., 2020b). The general 122 
symptoms observed in the infected individuals are fever, cough, dyspnoea and lesion 123 
in the lungs (Huang et al., 2020). In the advanced stage, the symptoms of this virus 124 
show pneumonia which progresses to severe pneumonia and acute respiratory distress 125 
syndrome (ARDS) which results in to the need for life-support to sustain the patient’s 126 
life (Heymann and Shindo, 2020). 127 
3. Structural Assembly of SARS-CoV-2 Virus 128 
The SARS-CoV-2 belongs to the largest family of the RNA viruses and its 129 
genome ranges from 27 to 32 kilobases in size (~125 nanometers or 0.125 microns). It 130 
is a single stranded enveloped RNA virus which possess a positive-sense RNA 131 
genome also known as (+ssRNA) with a 5’-cap structure and 3’-poly-A tail (Chen, 132 
2020). The viruses belonging to this category, have a few common characteristics that 133 
are applicable to SARS-CoV-2 as well. The virus has four important structural 134 
proteins which are (E) the envelope protein (M) the membrane protein (S) the spike 135 
protein and (N) the nucleocapsid protein, which are required to regulate the function 136 




most important ones are N and S, where the former one helps the virus to develop the 138 
capsid and the entire viral structure appropriately and the later one helps in the 139 
attachment of virus to the host cells (Siu et al., 2008; Walls et al., 2020). The S 140 
protein has three major sections which are, the large ectodomain, a single-pass 141 
transmembrane anchor and a short intracellular tail. These play a major role in 142 
anchoring the host cells. Among these sections the ectodomain has two subunits 143 
which are, the S1 receptor-binding subunit and S2 the membrane fusion subunit. 144 
These subunits are in the clove-trimeric or crown structure which is the reason 145 
coronavirus (corona = crown) got its name (Zumla et al., 2016).  146 
 It has been reported that the SARS-CoV and SARS-CoV-2 have similar kind 147 
of receptors, especially the receptor binding domain (RBD) and the receptor binding 148 
motif (RBM) in the viral genome (Yin and Wunderink, 2018; Zhang et al., 2020; Tai 149 
et al., 2020). During the SARS infection, the RBM of the S protein gets directly 150 
attached to the Angiotension-Converting Enzyme 2 (ACE2) in the human or the host 151 
cells (Phan, 2020). The ACE2 protein is expressed in various organs of the human 152 
body mainly in the lungs, kidney and intestine, the prime targets of the coronavirus 153 
(Zhao et al., 2020). The ACE1 and ACE2 have gained recognition as significant 154 
regulators of the physiology and pathology of the reproductive system (Pan et al., 155 
2013). Although, due to the novel nature of the virus, no study has proven that it will 156 
reduce men’s fertility or sexual potency but medics in Wuhan have suggested the 157 
likelihood that the disease can affect the production of sperm leading to low sperm 158 
count and the formation of male sex hormones (low libido). In addition, SARS-CoV-2 159 
infects host cell through ACE2 receptors leading to COVID-19 related pneumonia, 160 
while also causing acute myocardial injury and chronic damage to the cardiovascular 161 




Interestingly, it has also been proposed that SARS-CoV-2 mechanism of 163 
action in infection of humans is similar to the SARS. It has been reported that the 164 
RBM of the SARS-CoV-2 has a major amino acid residue (Gln493) that favours the 165 
attachment and fusion of the viral S protein with virus into the ACE2 protein of the 166 
human cell especially the one present in the lungs which results in respiratory 167 
infections in humans (Zhao et al., 2020; Yin and Wunderink, 2018). An illustration 168 
about the structure and binding of S protein to ACE2 has been depicted (Fig.1). The 169 
simplest and most direct approach to combat SARS-CoV-2 would be to neutralize the 170 
virus from entering cells as this has been utilized in previous viruses of its kind 171 
(Walker and Burton, 2018). The key advantage here is the host ACE2 protein does 172 
not change, so there is no fear about advantageous mutations that may hinder drug 173 
development (Karakus et al., 2020). These findings suggest that an in-depth 174 
knowledge about the receptors and its targets and basis of viral replication would be a 175 
stepping stone to find a remedy for the SARS-CoV-2 infection.  176 
4. Replication of SARS-CoV-2 177 
After the SARS-CoV-2 virus has entered the human host cells, the next step 178 
for its survival is its RNA replication. The viral RNA replication is the most unusual 179 
and critical step carried out by the virus for its survival inside the host body. The tools 180 
that are required for the process of replication are open reading frames (ORFs), two 181 
replicase genes (rep1a and rep1ab), a slippery sequence (5’-UUUAAAC-3’) and two 182 
polyproteins (pp1a and pp1ab). Both these polyproteins contain the most important 183 
proteins of the virus that are the Nsp proteins (Nsp1-11and Nsp1-16), these proteins 184 
are a common occurrence in these virus types (Baranov et al., 2005). Recently, it has 185 
been found that, the Nsp 15 protein not only has a vital role in replication but also 186 




2020). Further these Nsp proteins (Nsp1/2, Nsp2/3 and Nsp3/4) assemble to form the 188 
replicase-transcriptase complex (RTC) which creates an environment inside the host 189 
body suitable for RNA synthesis and replication. Also, these Nsps have various roles 190 
in RNA replication of the virus. Nsp12 codes for the RNA-dependent RNA 191 
polymerase (RdRP) domain, Nsp13 is encrypted with RNA helicase domain and RNA 192 
5’-triphosphase, Nsp14 encodes exoribonuclease (ExoN) which helps in replication 193 
conformity and finally Nsp16 encodes 2’-Omethyltransferase activity. These 194 
evidences prove that Nsp protein has a vital role in keeping the virus alive inside the 195 
host body by promoting basic synthesis, replication and translation.  196 
The process of replication in the SARS-CoV-2 similar to SARS-CoV virus is 197 
multifaceted and needs more understanding (Fehr and Perlman, 2015; Zhang et al., 198 
2020). For replication, the genomic RNA contains a 5’ end region that has the 199 
untranslated leader (L) sequence with the transcription regulation sequence (TRS) 200 
present at the descending region of the genome (Brian and Baric, 2005). The replicase 201 
gene encoded enzymes uses the negative RNA genome as a template to develop a few 202 
sets of small, overlapping messenger RNA (mRNA) molecules that further gets 203 
translated into the structural proteins viz, (N, M, E and S protein) also known as the 204 
building block for the production of new viral particles inside the host body, while the 205 
positive stranded RNA genome is used as a template to produce the negative strand. 206 
During the replication process inside the human host, the N protein of the virus binds 207 
to the genome while the M protein is associated with the membranes of the 208 
endoplasmic reticulum (ER). Further with the help of Nsp proteins the RNA gets 209 
assembled into a helical twisted structure and buds into the ER lumen. Viral progenies 210 
are transferred to the cell membranes by the Golgi bodies and exocytosed into the 211 




discovered in the preceding viruses and may have a pivotal role in SARS-CoV-2 as 213 
well (Brian and Baric, 2005; de Haan and Rottier, 2005). From the replication process 214 
of the SARS-CoV-2 it is evident that targeting Nsp proteins could enable us to 215 
develop a strategy to overcome this viral infection. Other than replication, other 216 
pathways associated with the virus can also be targeted for drug development. 217 
5. SARS-CoV-2- proposed mechanism 218 
SARS-CoV-2 shares homology with the SARS-CoV but the rate of 219 
transmission and infectivity of the SARS-CoV-2 has been remarkable; this 220 
accelerated spreading rate may be due to a gain of function mutation, making this 221 
novel virus different from the SARS-CoV virus. These changes found in SARS-CoV-222 
2 include, an absent 8a, longer 8b and shorter 3b segments and different Nsp 2 and 3 223 
proteins (Wu et al., 2020; Xu et al., 2020). Nsp 2 of SARS-CoV-2 consists of 224 
mutation that is probably associated with the ability of the virus to be more 225 
contagious (Angeletti et al., 2020). In addition, the orf8 and orf10 proteins are also 226 
different in SARS-CoV-2. It may be beneficial to understand the biological function 227 
of these proteins. Further, it has been found that more pathogenic viruses contain a 228 
furin like cleavage site in the S protein, which is not present in SARS-CoV but 229 
present in the SARS-CoV-2 (Coutard et al., 2020). This may be the reason for 230 
increased virulence of SARS-CoV-2. Moreover, SARS-CoV-2 binds the same 231 
receptor as SARS-CoV, namely, ACE2 with much higher strength; this could be the 232 
reason for the increased transmission rate and its capacity to affect other species with 233 
such ease. The S protein has S1 on its N terminal and S2 at its C terminal, and the 234 
RBD is present at the S1 region. The S2 domain of the S protein consists of the fusion 235 
protein, a second proteolytic site (S2′), followed by an internal fusion peptide (FP) 236 




internal FP is identical between SARS-CoV-2 and SARS-CoV (Coutard et al., 2020). 238 
From previous studies it was suggested that SARS-CoV-2 might have a similar 239 
mechanism as like SARS-CoV to enter the host cell. 240 
The SARS-CoV-2 like other beta-coronaviruses undergoes a few steps to enter 241 
into and affect the host cell. SARS-CoV-2 binds to same ACE2 receptor present in the 242 
respiratory epithelium and alveoli of the lungs (Liu et al., 2020). In SARS-CoV, upon 243 
binding to the receptor, proteases are recruited to cleave the S protein into S1 and S2 244 
domains. This cleavage induces a conformational change that activates S2, this is 245 
followed by the insertion of the FP into the membrane and membrane fusion occurs 246 
facilitating the entry of the virus into the cell. Since the nucleotides are conserved in 247 
RBD binding motif that is associated with ACE2, it is possible that SARS-CoV-2 248 
utilizes the same mechanism as well. Once the virus enters the cell, ACE2 gets 249 
cleaved and shed by ADAM17 into the extra membrane space. Reduced ACE2 has 250 
been known to be concomitant with alveoli injury and increases pulmonary vascular 251 
permeability (Li and Clercq, 2020). This could be due to the conversion of 252 
angiotensin I to angiotensin II by ACE2, which is a negative regulator of the renin-253 
angiotensin pathway. Angiotensin II stimulated ATIR results in the lung pathology 254 
associated with respiratory distress (Li and Clercq, 2020). Once the virus translates its 255 
proteins in the cell, the ORF3a protein is produced and codes for a Ca
2+
 ion channel 256 
that is similar to SARS-CoV and SARS-CoV-2. It interacts with TRAF3 and activates 257 
the transcription of the NF-kB pathway, resulting in the transcription of the pro-IL-1B 258 
gene (Siu et al., 2019), ORF3a along with TRAF3 also recruits the inflammasome 259 
complex. This complex consists of NLRP3, ASC and caspase 1. A second signal such 260 
as Ca
2+
 influx, caspases activation, ROS production and mitochondrial damage 261 




protein also activates the inflammasome pathway through NLRP3, and this protein is 263 
longer in SARS-CoV-2 (Shi et al., 2019). The extra nucleotides present in this virus 264 
need to be further studied to figure out if that has caused an added advantage. The E 265 
protein forming an ion channel, is also conserved in the two viruses and is involved in 266 
the overproduction of cytokines through the NLRP3 inflammasome pathway (Nieto-267 
Torres et al., 2015). All these pathways combined together cause a cytokine storm 268 
resulting in respiratory distress a common symptom of COVID-19. Another pathway 269 
involved in SARS-CoV includes the JNK pathway; which is activated by ORF3a, 270 
ORF3b and ORF7a which may lead to an increased production of pro-inflammatory 271 
factors, escalating lung damage (Liu et al., 2014). The JNK pathway can also be 272 
considered as a target for SARS-CoV-2 as it also involves the proteins that are 273 
analogous in both viruses. 274 
During the infection of the virus, the most important part is the interaction 275 
with the host cell nucleases. It is possible that SARS-CoV-2 may use proteases 276 
similar to SARS-CoV such as TMPRSS11a, Trypsin, Plasmin, Cathepsin L and Furin 277 
in the cleavage of the spike protein for the virus to enter the cell. These proteases can 278 
be used as targets to reduce the symptoms of COVID-19 as proteasomal inhibitors 279 
used for HIV treatment are being used in treatment of COVID-19 (Fig.2). A target for 280 
the COVID-19 may be advantageous to understand the involvement of the immune 281 
system in COVID-19, to explore the possibility of developing specific vaccines for it, 282 
as elucidated for previous viruses (Simmons et al., 2013).  283 
6. SARS-CoV-2 and the immune system 284 
The HCoVs generally are very long (30,000 bp) positive-sense single-stranded 285 
RNA viruses. Two groups of protein characterize HCoVs; the structural proteins, and 286 




(Elfiky, 2020). Coronaviruses such as SARS and MERS are particularly adept at 288 
evading immune detection and dampening immune responses. Its not yet clear how 289 
SARS-CoV-2 affects the immune system. During viral infection, host factors elicits 290 
immune response against the viruses. T cells, particularly CD4+ and CD8+ play a 291 
significant antiviral role to combat the pathogens and elevate the risk of developing 292 
autoimmunity/inflammation (Cecere et al., 2012). The CD4+T cells advance the 293 
production of viral‐ specific antibodies by activating T cell‐ dependent B cells. 294 
However, CD8+ T cells are cytotoxic and kill virus infected cells. The CD8+ T cells 295 
account for about 80% of total inflammatory cells in the pulmonary interstitium in 296 
SARS-CoV infected patients and play a critical role in clearing coronaviruses in 297 
infected cells and inducing immune injury (Maloir et al., 2018). In addition, T helper 298 
cells make proinflammatory cytokines via NF-kB signaling (Manni et al., 2014). The 299 
cytokines, IL-17 recruit monocytes and neutrophils to the infection site showing 300 
inflammation and activates other downstream cascades of cytokines and chemokines, 301 
including IL-1, IL-6, IL-8, IL-21, TNF-β, and MCP-1(Bunte and Beikler, 2019). It 302 
was observed that, T cell apoptosis was induced by a novel BH3-like region located in 303 
the C-terminal cytosolic domain of SARS-CoV protein mediated by Bcl-xL (Yang et 304 
al., 2005). From the experimental evidences it was shown that T cell response to S 305 
protein and other structural proteins (including the M and N proteins) is long-lasting, 306 
persistent and provides evidence for designing new drugs and vaccines for SARS-307 
CoV-2 composed of viral structural proteins, which can induce dominant, effective, 308 
and long-term memory cell responses against the virus. However, earlier studies have 309 
also reported a crucial role of both CD8+ and CD4+ T cells in SARS-CoV clearance 310 
(Chen et al., 2010), while Janice et al. (2012) also observed that development of 311 




the ACE2 protein fused to a human immunoglobulin G Fc domain (ACE2-Fc) of 313 
SARS-CoV-2 patients may have the benefits of a traditional neutralizing antibody 314 
which could be used as a treatment for the infection. Ultimately, there will be a need 315 
for clinical trials to delineate any specific side effects of ACE2-Fc treatment (Kruse, 316 
2020). Therefore ACE2-Fc might play an important role in the treatment of SARS-317 
CoV-2, if the function of ACE2-Fc is inhibited (Kruse, 2020). These immunological 318 
studies show how crucial it is to understand the basics of the immune responses in 319 
these viruses, so these immune cells can be induced to further attack the virus with 320 
increased specificity. Besides the immune system, scientists have also found a 321 
possible involvement of the COVID-19 in the nervous system. 322 
7. Neuroinvasion of HCoVs: 323 
The COVID-19 are not always confined to the respiratory tract, but they also 324 
invade the Central Nervous System (CNS) to induce neurological diseases. 325 
Coronaviruses with such potential are the beta-coronaviruses, including SARS-CoV 326 
(Glass et al., 2004), MERS-CoV (Li et al., 2016), HCoV-229E (Talbot et al., 1994), 327 
HCoV-OC43 (Dubé et al., 2018), mouse hepatitis virus (MHV) (Zhou et al., 2017), 328 
and Porcine Hemagglutinating Encephalomyelitis Virus (PHEV) (Mengeling et al., 329 
1972). According to previous study, coronaviruses may initially invade peripheral 330 
nerves and enter the CNS via the synaptic route, where this trans-synaptic transfer has 331 
been documented in HEV67 and avian bronchitis virus (Matsuda, et al., 2004). The 332 
first coronavirus found to invade the porcine brain was HEV 67N, and it shares >91% 333 
homology with HCoV-OC43 (Li et al., 2016). Therefore, the neuroinvasive 334 
propensity has been demonstrated as a common feature of coronaviruses. Since there 335 
is a high similarity between SARS-CoV and SARS-CoV-2, it is quite likely that 336 




survey, the first symptom is dyspnea which occurs in 5 days, followed by hospital 338 
admission at 7 days, and intensive care at 8 days for COVID-19 (Wang et al., 2020). 339 
This latency period is enough for the virus to enter and destroy the medullary neurons. 340 
A possible mechanism about the entry of SARS-CoV-2 inside the CNS has been 341 
illustrated (Fig.3). Similarly, Mathew (2020) stated that the symptoms might attribute 342 
to respiratory disease is due to the inability of air to get into the lungs, that might 343 
actually be the defects in respiration controlled by the nervous system. It has been 344 
reported that some COVID-19 patients showed neurologic signs, including headache 345 
(about 8%), nausea and vomiting (1%). As the neuroinvasion of SARS-CoV-2 is 346 
accompanied by respiratory failure in COVID-19 patients, the entry of the virus into 347 
the CNS must be prevented. As an emerging virus, awareness of the possible entry of 348 
SARS-CoV-2 into the CNS is significant for prevention and treatment. It is also 349 
important to find effective antiviral drugs that can cross the blood-brain barrier (Li et 350 
al., 2020). Therefore, more innovative approaches are required to detect this viral 351 
infection at an earlier period. 352 
8. Recent diagnostic techniques 353 
 354 
During the SARS and MERS outbreaks effective diagnostic tools were 355 
developed for accurate detection. Although, useful at that time, it is now essential to 356 
develop specific tests for COVID-19. The viral nucleic acid detection is primarily 357 
used in SARS-CoV-2 diagnosis (Wang et al., 2020). CDC has recommended the 358 
collection of upper respiratory nasopharyngeal (NP) swabs for the diagnostic tests 359 
(CDC, 2020). The CDC detection assay targets the N region and consists of one test 360 
for beta-coronaviruses and two unique probes for SARS-CoV-2. The Charité 361 
algorithm comprises of probes for E protein and RA-dependent RNA polymerase 362 




CoV-2 RdRp (Loeffelholz and Tang, 2020). Contrastingly, the E protein with RdRp 364 
was also detecting SARS-CoV, and so, these assays can be used to test for the SARS-365 
CoV-2 when there are no traces of SARS-CoV (Cordes and Heim, 2020). When the 366 
commercially available Real Star kit, Virus +Rox Vial kit and Super Script III One-367 
step RT-PCR System with Platinum TaqDNA Polymerase were compared for their 368 
efficiency, the RealStar Kit did not have any unwanted signals and exceeded the other 369 
two in its performance (Konrad et al., 2020). These methods can also be compromised 370 
due to inadequate sample volume, inaccuracies in methods of testing, not collecting 371 
samples at the appropriate time window, and contamination. Similar issues have been 372 
identified as potential problems that may diminish the precision of the tests (Lippi et 373 
al., 2020). Moreover, these tests are also expensive, hence cheaper alternatives have 374 
been developed to track the symptoms of COVID-19 using smart-phone surveillance 375 
(Dorigatti et al., 2020). Imaging techniques can also be utilized as a diagnostic 376 
method in COVID-19. Additionally, chest CT scans have been facilitated to detect 377 
lung abnormalities in this SARS-CoV-2 infection (Shi et al., 2020; Xu et al., 2020). 378 
Abnormalities in the CT scans can be concomitant with disease progression and 379 
prognosis. But, not all the cases can be perfectly detected with CT scans (Lei et al., 380 
2020). Therefore, it is essential to conduct molecular tests and consider travel history 381 
and clinical symptoms of the patient as well. As there are an upsurge of infected 382 
people, more efficient, quicker and cheaper diagnostic tools must be developed to 383 
effectively identify infected individuals. Hence, the integrated approach of imaging 384 
and molecular diagnosis would help in screening and treating COVID -19 effectively. 385 
In order to design these specific drugs, it is important to understand the current 386 
strategies used to treat this novel COVID-19 387 




 Though the number of affected individuals is constantly on the rise, there are 389 
no FDA approved drugs for COVID-19 yet. At present, treatment provided to the 390 
affected individuals are mainly symptom based, and the seriously ill individuals are 391 
provided with organ support (Jin et al., 2020; Zumla et al., 2020). It is necessary to 392 
invest time and effort in identifying vaccines and drugs for this novel virus. Since the 393 
development of drugs specific for COVID -19 will take at least a few months drugs 394 
which have been proven to be safe for humans can be repurposed to treat this disease. 395 
The vast majority of the drugs used for treatment worldwide falls under any of the 396 
following classification of drugs. 397 
9.1. Antiviral drugs - Drugs under this category usually follow either of the 398 
following three mechanisms in the virus-viral replication inhibition, ion channel 399 
inhibition and serine protease inhibition. Commercially available antiviral drugs 400 
mostly target the four major groups of viruses: human immunodeficiency virus (HIV), 401 
herpes, hepatitis and influenza (Razonable, 2011). Earlier outbreak episodes of viral 402 
infections like SARS-CoV and MERS-CoV as well as hemorrhagic fever viruses like 403 
Ebola were treated with this category of drugs (De Clercq, 2007). 404 
9.2. Antimalarial drugs - These drugs also fall under three categories based on their 405 
mode of action aryl amino-alcohol compound, antifolate compound and artemisinin. 406 
Most of these drugs are eliminated gradually from the body remaining for long 407 
periods of time after intake. A disadvantage of this drug is that antimalarial drug 408 
resistance develops for any drugs under this category (Edwin et al., 2019). 409 
9.3. Anti-HIV drugs - These drugs are classified into different categories based on 410 
their targets reverse transcription, retro-transcription, proteolytic processing, viral-cell 411 
fusion, co-receptors interactions and incorporation of proviral DNA into the host 412 




and Drug Administration) and are now officially used for the treatment of HIV (De 414 
Clercq, 2009). 415 
9.4. Anti-inflammatory drugs - Huge inflammatory response is observed in COVID-416 
19. Anti-inflammatory drugs especially JAK-STAT inhibitors, used against 417 
rheumatoid arthritis, may be effective against elevated levels of cytokines and useful 418 
in inhibiting viral infection. According to recent study, an inflammatory drug, 419 
baricitinib when used in combination with anti-viral drugs like Remidesivir, increases 420 
the potential of the drug to reduce viral infection (Stebbing et al., 2020). 421 
9.5. Monoclonal antibodies - The virus is known to enter the host cells by binding 422 
the S protein to ACE2 receptors. By developing neutralizing antibodies against the 423 
receptors, there is a high possibility for reducing the severity of the disease (Zheng 424 
and Song, 2020). Currently, only a handful of drugs have been approved for use 425 
against SARS-CoV-2. 426 
10. Clinically Used Drugs 427 
Even before the declaration of COVID-19 as a pandemic by WHO, there was 428 
an immense lack of disease specific drugs. Being a rapidly spreading virus, it is 429 
essential to provide timely treatment for the affected individuals (Zumla et al., 2016). 430 
A list of potential drugs is provided in Table 2 and a few of the commonly used drugs 431 
are discussed below; 432 
10.1. Ribavirin - Ribavirin is also a broad-spectrum drug whose therapeutic potential 433 
was uncovered during 1972. This antiviral drug is used in the treatment of hepatitis C. 434 
It is usually used in combination with interferon α (IFN). This drug, approved by the 435 
FDA, competes for the active site of RdRp. Ribavirin scored 109.5 µM of half 436 




10.2. Sofosbuvir - This drug is also an FDA approved drug against NS5B and acts as 438 
a nucleotide polymerase inhibitor used for the treatment of hepatitis C. It was used in 439 
combination with interferon or RBV. This drug was previously used for the treatment 440 
of Zika virus (Cheema et al., 2019). 441 
10.3. Lopinavir/Ritonavir - Lopinavir is a protease inhibitor which targets the HIV 442 
virus. It was identified by 1998 and approved by the FDA by 2000. This drug 443 
prevents the formation of viral proteins by disrupting the proteolytic processing by 444 
mimicking its structure as a peptide cleaved by HIV protease. This drug along with 445 
another flu drug oseltamivir was reported to result in complete recovery after showing 446 
signs of COVID-19 related pneumonia (Wu et al., 2020). 447 
10.4. Remidesivir (anti-viral peptide) - This particular drug is an adenosine 448 
nucleotide analog, which was used in treatments against Ebola, SARS-CoV and 449 
MERS-CoV. It is a promising and potential drug which causes premature termination 450 
by entering the nascent viral RNA (Warren et al., 2016). Currently, it is undergoing 451 
clinical trials for Ebola treatment (Mulangu et al., 2019). Another recent study has 452 
shown that Remidesivir scored 0.77 µM at half maximal concentration against 453 
COVID-19 and blocked viral infection (Wang et al., 2020). 454 
10.5. Chloroquine - This drug, classified as an anti-malarial drug, has shown 455 
potential in the treatment of avian influenza A (Yan et al., 2013). Chloroquine also 456 
has shown to have anti-viral as well as immune modulating properties. This drug also 457 
showed 1.13 µM at half maximal concentration against SARS-CoV-2 and blocked 458 
viral infection by increasing the endosomal pH required for viral fusion (Wang et al., 459 




10.6. Favipiravir - This drug is also a broad spectrum anti-viral drug which has 461 
obtained approval from Shenzan Health Commission for treating COVID–19 patients 462 
(Wu et al., 2020). 463 
10.7. Ongoing Clinical Trials 464 
Currently, there are numerous companies that have applied for clinical trials to 465 
repurpose existing drugs as well as to develop vaccines and drugs to fight against the 466 
fast spreading COVID–19 (Rudra, et al., 2017). In the case of repurposing the existing 467 
drugs, randomized controlled treatment (RCT) are being carried out by various 468 
biotechnological companies as well as research organizations such as National 469 
Institutes of Health (NIH), USA to identify disease specific drugs. The major drugs 470 
undergoing clinical trials that have the potential to treat this viral infection (Table 3). 471 
More research may be required in traditional medicine to utilize them in the treatment 472 
of COVID-19.  473 
10. Importance of Indian Medicine 474 
Indian traditional medicinal systems are considered as one of the oldest 475 
treatments in human history and it plays an important role in encountering global 476 
health care needs (Ravishankar and Shukla, 2007). Traditional Indian medicinal 477 
practices include Ayurveda, Siddha, Unani and Yoga, Naturopathy and 478 
Homoeopathy, which are successfully practiced for treating various diseases 479 
(Gomathi et al., 2020). These practices came into existence 5000 years ago, and these 480 
systems have been witnessed and scripted in ancient literature. 481 
 Traditional Indian medicine use plants, minerals and animal products for 482 
curing human diseases. Traditional knowledge regarding the plant sources and their 483 
usage are essential to use them accurately and for the right condition (Tabuti et al., 484 




Indian medicine (Pundarikakshudu and Kanaki, 2019). Recently, the total number of 486 
Indian medicinal plants was estimated to be around 3000, yet, traditional practitioners 487 
use around 8000 different species for their practice (Pundarikakshudu and Kanaki, 488 
2019). Traditional medicines are generally ignored in research and development of 489 
modern drugs since their translational potentials are often underestimated. Although 490 
these medicines are ambiguous, there are wide contexts for their usage in non-491 
Western medical technology (Yuan et al., 2016). A single herb may contain many 492 
phytochemical constituents that function alone or in combination with other 493 
compounds to produce the desired pharmacological effect (Parasuraman et al., 2014). 494 
Due to their use in traditional medicine, many plant molecules have been studied and 495 
subsequently modulated into drugs for various diseases (Li-Weber, 2009; Fabricant 496 
and Farnsworth, 2001). The search for new compounds with antiviral activity has 497 
often been unsatisfactory due to viral resistance along with viral latency and recurrent 498 
infection in immune-compromised patients (Sumithira et al., 2012). Among antiviral 499 
therapeutic methods, the majority of them are non-specific for viruses (Jiang et al., 500 
2015),The advancements in developing antiviral agents are the major focus in medical 501 
research. The antiviral effects of medicinal plants have played a tremendous role at 502 
different stages of viral growth (Akram et al., 2018). Plant derived pharmacological 503 
formulations marked a major contribution for viral infections (Cragg et al., 1997). 504 
Based on the availability of suitable, efficient and rapid bioassay systems, the 505 
antiviral compounds have been used for rapid screening from plant extracts and 506 
fractions (Scior et al., 2012). Instead of synthetic antiviral drugs, medicinal plants 507 
deliver basic raw materials for important antiviral drugs (Moghadamtousi et al., 508 
2015). Synthetic drugs have been replaced by medicinal plants, as life-saving drugs 509 




medication have been passed down to generations by word of mouth and most of 511 
them have been lost over time, due to the lack of proper documentation. Research on 512 
these herbs and medicinal plants may help to promote their usage in clinical settings 513 
to prevent or treat various illnesses. Since many Indian medicinal plants exhibit 514 
antiviral, anti-inflammatory and antioxidant properties, it may be favorable to 515 
consider them for the treatment of COVID-19. It is clear that standard clinical trials 516 
should be carried out to scientifically prove its efficacy. 517 
11. Indian medicinal plants and their possible effect on COVID-19 518 
Since ancient times, Indian herbs have been used as a treatment and preventive 519 
strategy for several diseases, including respiratory viral infections. The benefit of 520 
using these herbs in viral respiratory infections is to build immune stimulating and 521 
inflammation modulating effects of manage the immune system. Holistic approach of 522 
AYUSH systems of medicine gives focus on prevention through lifestyle 523 
modification, dietary management, prophylactic interventions for improving the 524 
immunity and simple remedies based on presentation of the symptoms (AYUSH, 525 
2020). Indian preventive and prophylactic medicinal plants recommended by AYUSH 526 
for COVID-19 (Table 4). Also, other studies on coronavirus using medicinal plants 527 
are rather minimal in India, a study has shown anti-mouse coronaviral activity (a 528 
surrogate of SARS-CoV) by the plants  Indigofera tinctoria (AO), Vitex trifolia, 529 
Gymnema sylvestre, Abutilon indicum, Leucas aspera, Cassia alata, Sphaeranthus 530 
indicus, Clitoriaternatea, Clerodendruminerme Gaertn, Pergulariadaemi and 531 
Evolvulus alsinoides in Tamil Nadu (Vimalanathan et al., 2009). Among them Vitex 532 
trifolia and Sphaeranthus indicus have been found to reduce inflammatory cytokines 533 
using the NF-kB pathway, a pathway that has been implicated in respiratory distress 534 




identified as a metalloproteinase inhibitor, ADAM17, a metalloproteinase that is 536 
involved in ACE shredding can be targeted using this plant, as ACE-2 shredding has 537 
been associated with an increased formation of viruses (Maity et al., 2012). The plants 538 
Glycyrrhiza glabra (Nourazarian, 2015) and Allium sativum (Keyaerts et al., 2007) 539 
have been known to target the viral replication of SARS-CoV, arising as promising 540 
candidates against SARS-CoV-2. Clerodendrum inerme Gaertn , another herb has 541 
been found to have the potential to inactivate the viral ribosome, this can be further 542 
investigated for its utility as a drug targeting SARS-CoV-2 protein translation 543 
(Olivieri et al., 1996). Similarly, Strobilanthes Cusia (Tsai et al., 2020) blocked the 544 
viral RNA genome synthesis and induced papain like protease activity targeting the 545 
HCoV. In Asia, Himalayan forests are abundantly flourished with rich medicinal plant 546 
species and a study has documented the presence of ethnomedicinal plants against 547 
bronchitis (Amber et al., 2017). The study screened the antiviral plant properties 548 
against bronchitis, which showed that Hyoscyamus niger, Justicia adhatoda and 549 
Verbascum thapsus reduced infections caused by influenza viruses. The molecular 550 
mechanism by which these plants target influenza virus can be studied to understand 551 
if they attack any molecules overlapping between SARS-CoV-2 and the Influenza 552 
viruses.  Hyoscyamus niger was found to be a bronchodilator and also had inhibitory 553 
effects on Ca
2+
 channel (Gilani et al., 2008). This could be used to target the orf3a 554 
Ca
2+
channels that trigger various downstream pathways upon viral infection.   Most 555 
importantly, various medicinal plants have shown inhibitory effects against ACE, and 556 
these include Coriandrum sativum (Hussain et al., 2018), Boerhaavia diffusa, Cynara 557 
scolymus ,Coscinium fenestratum, Punicagranatum Cassia occidentalis 558 
and Embeliaribes. Among them, Punicagranatum showed a competitive mode of 559 




et al., 2013). These plants need to be studied further to examine their actual effects on 561 
the entry of SARS-CoV-2 into the host cell. One of the tropical species in the 562 
Acanthaceae family, Andrographis paniculata (kalmegh) present in South Asia has a 563 
strong treating capacity of viral respiratory infections in Ayurvedic and other 564 
medicinal systems (Yarnell, 2018; Arora et al., 2011; Coon and Ernst, 2004). It was 565 
noted that Andrographis paniculata suppressed increased NOD-like receptor protein 3 566 
(NLRP3), caspase-1, and interleukin-1β molecules which are extensively involved in 567 
the pathogenesis of SARS-COV and likely SARS-CoV-2  as well (Liu et al., 2020). 568 
Salacia oblonga (He et al., 2011) another plant from Tamil Nadu has also displayed 569 
suppressive effects on angiotensin II, AT1 signal, which was related to lung damage. 570 
Many plants have also shown inhibitory actions towards HIV proteases, these plants 571 
can be promising drugs for COVID-19. They include, Acacia nilotica (Shanti, 2016), 572 
Eugenia jambolana (Otake et al., 1995), Euphorbia granulate (Shanti, 2016). Some 573 
plants like Ocimum sanctum (Rege and Chowdhary, 2014), Ocimumkilim and 574 
scharicum (Thayil Seema and Thyagarajan, 2016), Solanum nigrum (Yu, 2004), Vitex 575 
negundo (NAIR, 2012) have been known to target the reverse transcriptase activity of 576 
HIV and can be studied for activity against SARS-CoV-2 as well. Further, Sambucus 577 
ebulus (Ganjhu et al., 2015) has been known to inhibit the activity of enveloped 578 
viruses and can also be used to target this virus. These medicinal plants can be used to 579 
ameliorate the symptoms of COVID-19. Though many medicinal plants have been 580 
identified, a lot of research has to be carried out for the development of drug specific 581 
to SARS-CoV-2. Therefore, it is important to explore the effect of these prescribed 582 
traditional medicines on SARS-CoV-2 (Table.5). Various Indian medicinal plants that 583 





12. COVID-19- The global challenges 586 
COVID-19 has emerged as the most dangerous pandemic threat through-out 587 
the globe since its outbreak during December 2019. It has become a big challenge for 588 
the researchers and virologist to find a solution for this deadly disease. This is 589 
attributed to the fact that COVID-19 is a viral infection that has been known to have 590 
the fastest frequency of recombination or replication in its positive strand resulting in 591 
the quick formation of new progeny viral cells inside the host cells. It has also been 592 
reported that SARS-CoV-2 has a high rate of mutagenesis and changes in structure, 593 
which has created a barrier for both investigations of the disease and therapeutic 594 
regimens (American society for microbiology, 2020). Recently, few researchers have 595 
identified that the SARS-CoV-2 has mainly two types of strains, which are the ‘L’ 596 
and ‘S’ strains. Among these strains the L strain is more common and may have 597 
evolved from the S strain; additionally, this L strain has a higher rate of replication 598 
inside the human host cell, which has resulted in the escalation of the infection in 599 
limited time. Hence, it has become a big challenge to analyze the condition and offer 600 
therapy at the short time available. Due to the high mutation rate, it has been harder to 601 
understand the genomic organization and host interaction of the virus (Habibzadeh 602 
and Stoneman, 2020). 603 
The genomic structure of the virus is not the only factor that presents a great 604 
challenge to research, its ability to adapt and survive in different environmental 605 
conditions make it nearly impossible to identify its mode of survival. It has been 606 
earlier reported that the SARS virus can survive at 4°C with a humidity rate of 20%. 607 
The first outbreak of the SARS-CoV-2 was during the peak of winter, where the 608 
environmental temperature was around 2°C to 10°C. But since then the virus has 609 




making its demographic association hard to predict. The health care professionals and 611 
equipment are limited and are unable to handle the vast number of patients who are 612 
infected. Moreover, some of the individuals who are infectious are asymptomatic and 613 
continue to travel or gather in social surroundings infecting more people. These 614 
factors pose a challenge for scientists, health-care professional and government 615 
officials to handle and contain the condition. Government officials in all countries 616 
continue to make efforts to minimize human contact by facilitating country wide 617 
shutdowns of public places as well as various steps have been initiated to ensure the 618 
safety of the people, like social distancing and self-quarantine which limits our social 619 
interactions. This will reduce the risk of spreading the COVID-19 to people by 620 
breaking the transmission chain and the influx of new COVID-19 cases in a given 621 
time period (Balachandar et al., 2020). 622 
13. Concluding Remarks 623 
Over the past few decades, there was an urge to discover the root cause of 624 
coronavirus infections not only in animals but in humans as well. Currently, COVID-625 
19 has emerged as the most intense and petrifying viral infection to be handled by the 626 
human race. According to WHO (2020b), major concern among public health 627 
throughout the world and many countries have taken precautionary measures against 628 
the virus, and Government officials in all countries continue to make efforts to 629 
minimize human contact by facilitating countrywide shutdowns of public places as 630 
well as various steps have been initiated to ensure the safety of the people, like social 631 
distancing and self-quarantine which limits our social interactions (Balachandar et al, 632 
2020). This will reduce the risk of spreading the COVID-19 to people by breaking the 633 
transmission chain and the influx of new COVID-19 cases in a given time period. 634 




confirmed deaths are 18,589 (WHO, 2020a) as on 26
th
 March 26, 2020 and in India 636 
581 cases (ICMR, 2020) have been identified to be positive for this COVID-19 and 637 
11 death cases in India as on 25
th
 March 2020 (20:00 IST).  More cases are likely to 638 
be identified in the coming days in India. This increase in infection was mainly due to 639 
the ability of this virus to recombine, mutate, block the immune system of the host 640 
cells and infect multiple species as well as cell types. Moreover, discovering the gene 641 
pool of SARS-CoV-2 may help accelerate the production of drugs and vaccines. 642 
Further, analyzing and understanding the role of non-structure and accessory proteins 643 
encrypted in this virus will aid us in understanding its mechanism of action. Also, 644 
acquiring an in-depth framework of its unique RNA replication process will enable us 645 
to find a breakthrough point to understand the host immunological response. Our 646 
review suggests the importance of a few Indian medicinal plants that have been used 647 
for several decades in the treatment of various respiratory conditions. It highlights the 648 
pathways that the plant-based medicines may target to reduce the disease burden. 649 
Thus, proactive investments in researches based on Indian medicinal plant derived 650 
vaccines or drugs to treat COVID-19 would emerge as a source of light to overcome 651 
this fatal infection. 652 
14. Recommendations 653 
The cases reported in many parts of China and the outbreaks involve large 654 
numbers in Italy, USA, Spain and Germany; hence travel restrictions and quarantine 655 
measures have been placed in severely affected areas. The spectrum of symptoms 656 
associated with COVID-19 ranges from difficulties in breathing and other respiratory 657 
conditions to critical conditions including SARS, kidney failure and sometimes even 658 
death. Individuals are likely to be infected by others who have been inflicted with the 659 




mouth when a person with COVID-19 coughs or exhales. These particles in the air, 661 
settle on surfaces in the environment further infecting people who breathe these 662 
particles or touch these places and then touch their body parts. Hence, it is important 663 
to stay more than 1 meter (3 feet) away from a person who is sick (WHO, 2020c). 664 
Reports suggest that older persons and persons with pre-existing medical conditions 665 
(such as high blood pressure, heart disease, lung disease, cancer or diabetes) appear to 666 
develop serious illness more often than others, also pregnant women with the 667 
infection had did not pass the infection to their unborn babies (Wu and McGoogan, 668 
2020; Chen et al., 2020). Also it has been reported that some of the Asian populations 669 
are more susceptible to acquire this COVID-19 infection when compared to the other 670 
races populations (Xu, 2020). Following are the protective measures given by WHO 671 
(2020d),  672 
a) Wash hands completely using an alcohol-based hand sanitizer will kill the virus, 673 
b) Avoid touching eyes, nose and mouth when outside. 674 
c) Be updated about the virus. 675 
d) Avoid travelling or gathering in crowded places. 676 
e) Women with infants are encouraged to breastfeed their babies to enhance their 677 
immunity. 678 
WHO is coordinating efforts to develop vaccines and medicines to prevent and treat 679 
COVID-19 (WHO, 2020d). National Institutes of Health (NIH), has mentioned that 680 
SARS-CoV-2 could survive for up to three hours maximum as aerosols to a maximum 681 
of three days on surfaces. Slowing the spread of the COVID-19 cases will 682 
significantly reduce the strain on the healthcare system of the country by limiting the 683 
number of people who are severely sick by COVID-19 and need hospital care. It will 684 




time for all the citizens to join hands together to fight against coronavirus by 686 
practicing self-hygiene and social distancing.  687 
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Acute pneumonia, septic 
shock, respiratory failure 
in adverse condition. 
No vaccines available, 














Loss of appetite 
Diarrhoea 
 Sudden 2-7 days 
after 
exposure 
5- 6 Weeks Human to 
Human 
Heart, Liver and 
Respiratory failure in 
adverse condition. 




Antiviral medicines  














Sudden 5-6 days 
after 
exposure 
6-7 Weeks Human to 
Human 
Acute pneumonia 
Kidney failure in adverse 
condition. 
Treatment only for 










Low grade fever 




7-10 days  Human to 
Human 
Extremely rare or None Symptoms can be treated 
by medication. 
        
Table 1 represents the parallel investigation of Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), Novel Coronavirus (COVID-19) 
and Common Flu with their Symptoms, Onset of Disease, Incubation Period, Recovery, Transmission of Disease, Complications and available treatments. 
Table 1: Symptomatic comparison of COVID -19, SARS, MERS and Common Flu 
Table 1
Click here to download Table: Table 1.docx
 
                                   Table 2: The Detailed Report of Commercially Available Drugs in Treatment of COVID – 19  
 
S.No. Name of Drug Illnesses treated References 
1.  α-interferon 
Spectrum of respiratory infections¸ RSV and 
SARS 
(Cinatl et al., 2003; Guerrero et al., 2013; 
Markland et al., 2000) 
2.  Ritonavir and lopinavir SARS, MERS (Chu et al., 2004) 
3.  Ribavirin RSV and RSV pneumonia 
(Lewinsohn et al., 1996; McIntosh et al., 
1984) 
4.  
Reverse transcriptase inhibitors: 
zidovudine, didanosine, zalcitabine, 
stavudine, lamivudine, abacavir and 
emtricitabine. 
SARS (De Clercq, 2007) 
5.  
Nucleotide reverse transcriptase 
inhibitor: tenofovir disoproxil fumarate. 
SARS (De Clercq, 2007) 
6.  
Non-nucleoside reverse transcriptase 
inhibitors (NNRTIs): nevirapine, 
delavirdine and efavirenz. 
SARS De Clercq 2007 
7.  
Protease Inhibitors (PIs): saquinavir, 
ritonavir, indinavir, nelfinavir, 
amprenavir, lopinavir, atazanavir and 
fosamprenavir. 
SARS De Clercq 2007 
8.  
Fusion inhibitor: enfuvirtide. 
Lamivudine and adefovir dipivoxil. 
SARS De Clercq 2007 
9.  Umifenovir 
ARVI, influenza, rhinovirus, adenovirus, 
parainfluenza, respiratory syncytial virus, 
coronavirus, including the causative agent of 
(De Clercq, 2007) 
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atypical pneumonia 
Used in the phase III trials of 2019- nCoV 
virus, SARS, MERS 
10.  3-chymotrypsin-like protease SARS, MERS 
(Chou et al., 2008; Kilianski et al., 2013; Li 
and De Clercq, 2020) 
11.  Papain-like protease 
SARS, MERS and Human Coronavirus 
NL63. 
(Chen, 2020; Harcourt et al., 2004; Kilianski 
et al., 2013) 
12.  RNA-dependent RNA polymerase SARS, Murine Coronavirus. 
(Imbert et al., 2006; Lu, 2020; Mahy et al., 
1983) 
13.  Capsid spike glycoprotein (hCoV-EMC) SARS, Human Coronavirus 
(Gierer et al., 2013; Hoffmann et al., 2020; 
Howard et al., 2008) 
14.  
Guanosine-analog RNA synthesis 
inhibitors 
Coronavirus (Beaucourt and Vignuzzi, 2014) 
15.  Nitazoxanide SARS, MERS and Influenza (Rossignol, 2016)   
16.  Influenza drugs MERS (De Clercq, 2007) 
17.  Remdesivir COVID-19, SARS, MERS Agostini et al. 2018; Wang 2020 
18.  Favipiravir  COVID-19 (Wang, 2020)  
19.  Darunavir COVID-19 (Beck et al., 2020; Lin et al., 2020) 
20.  Lopinavir  COVID-19, SARS, MERS Yao et al. 2020  
21.  
Alcohol Vaporization or Nebulization 
Inhalation Therapy 
COVID-19 (Cao, 2020) 
22.  Chloroquine SARS, Human Coronavirus OC43. 
(Keyaerts et al., 2009, 2004; Vincent et al., 
2005) 
23.  ASC09 
ARDS, Respiratory distress syndrome, SARS, 
MERS 
(March and Bogatcheva, 2019, 2018) 
24.  TMPRSS2 inhibitor Camostat mesylate 
SARS, MERS, Coronavirus 229E and 
COVID-19 
(Bertram et al., 2013; Hoffmann et al., 2020; 
Kawase et al., 2012; Shirato et al., 2013) 
25.  Baricitinib COVID-19 
(Richardson et al., 2020; Stebbing et al., 
2020) 
26.  Ruxolitinib COVID-19 (Stebbing et al., 2020) 
27.  Saquinavir SARS and Feline Coronavirus  
(Blanchard et al., 2004; Comper, 2005; Hsieh 
et al., 2010) 
 
28.  Indinavir SARS and COVID-19 (Contini, 2020; Tan et al., 2004) 
29.  Carfilzomib COVID-19 (Wang, 2020) 
30.  Oseltamivir  COVID-19 (Haagmans et al., 2004; Lu, 2020) 
31.  Azvudine COVID-19 (Hu et al., 2020) 
32.  Baloxavir marboxil COVID-19 (Li and De Clercq, 2020) 
33.  Thymosin α1 MERS (Leyva-Grado and Behzadi, 2019) 
34.  Methylprednisolone SARS, MERS (Kim and Joh, 2006; Que et al., 2003) 
35.  Tocilizumab COVID-19 (Diao et al., 2020) 
36.  
Interferon Subtypes of β-1b, α-n1, α-n3, 
and human leukocyte interferon α 
SARS (Tan et al., 2004) 
37.  Acyclovir 
SARS, MERS, Coronavirus 229E and 
COVID-19 
(Peters et al., 2015) 
38.  Cathespin L SARS (Simmons et al., 2005) 
 
Table 2 represents the commercially available drugs used for the treatment of the various forms of coronaviruses. The viral infections discussed 
in the table are SARS - Severe Acute Respiratory Syndrome, MERS - Middle East Respiratory Syndrome, RSV - Respiratory Syncytial Virus, 





Table 3: Ongoing Clinical Trials for COVID – 19  
 
S.No. Study Drug Status Organization 
1.  
Evaluation of the Efficacy and Safety of 
Sarilumab in Hospitalized Patients With COVID-
19 
Sarilumab Recruiting 
Regeneron Study Site 
New York, New York, United States 
2.  
Study to Evaluate the Safety and Antiviral 
Activity of Remdesivir (GS-5734™) in 
Participants With Severe Coronavirus Disease 
(COVID-19) 
Remdesivir Recruiting 
1. Hoag Memorial Hospital Presbyterian 
Newport Beach, California, United States 
2.Stanford Hospital, Stanford, California, United 
States 
3. Providence Regional Medical Center Everett, 
Everett, Washington, United States 
3.  
Study to Evaluate the Safety and Antiviral 
Activity of Remdesivir (GS-5734™) in 
Participants With Moderate Coronavirus Disease 
(COVID-19) Compared to Standard of Care 
Treatment 
Remdesivir Recruiting 
1. Hoag Memorial Hospital Presbyterian 
Newport Beach, California, United States 
2.Stanford Hospital, Stanford, California, United 
States 
3. Providence Regional Medical Center Everett, 
Everett, Washington, United States 




The Clinical Study of Carrimycin on Treatment 
Patients With COVID-19 
1.Carrimycin 
2. Lopinavir/ritonavir tablets or 






Efficacy and Safety of Corticosteroids in COVID-
19 
Methylprednisolone Recruiting 
1. Hubei province hospital of integrated Chinese 
& Western Medicine 
Wuhan, Hubei, China 
2. Yichang first people's Hospital 
Yichang, Hubei, China 
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3. Renmin Hospital of Wuhan University 
Wuhan, China 
7.  Mild/Moderate 2019-nCoV Remdesivir RCT Remdesivir Recruiting 
Jin Yin-tan hospital 
Wu Han, Hubei, China 
8.  Adaptive COVID-19 Treatment Trial Remdesivir Recruiting 
1.National Institutes of Health - Clinical Center, 
National Institute of Allergy and Infectious 
Diseases Laboratory Of Immunoregulation, 
Clinical Research Section 
Bethesda, Maryland, United States 
2. University of Nebraska Medical Center - 
Infectious Diseases 
Omaha, Nebraska, United States 
3. University of Texas Medical Branch - 
Division of Infectious Disease 
Galveston, Texas, United States 
4. Providence Sacred Heart Medical Center 
Spokane, Washington, United States 
9.  Severe 2019-nCoV Remdesivir RCT Remdesivir Recruiting 
Bin Cao 
Beijing, Beijing, China 
10.  
Nitric Oxide Gas Inhalation for Severe Acute 
Respiratory Syndrome in COVID-19. 





Efficacy and Safety of IFN-α2β in the Treatment 
of Novel Coronavirus Patients 






Evaluating and Comparing the Safety and 
Efficiency of ASC09/Ritonavir and 
Lopinavir/Ritonavir for Novel Coronavirus 
Infection 
1.ASC09/ritonavir group 





Safety and Immunogenicity Study of 2019-nCoV 





Kaiser Permanente Washington Health Research 
Institute - Vaccines and Infectious Diseases 
Seattle, Washington, United States 
14.  
Glucocorticoid Therapy for Novel 
CoronavirusCritically Ill Patients With Severe 
Methylprednisolone Recruiting 
Medical ICU,Peking Union Medical College 
Hospital 
Acute Respiratory Failure Beijing, Beijing, China 
15.  
Lopinavir/ Ritonavir, Ribavirin and IFN-beta 
Combination for nCoV Treatment 
1. Lopinavir/ritonavir 
2.  Ribavirin 
3.  Interferon Beta-1B 
Recruiting 
University of Hong Kong, Queen Mary Hospital 
Hong Kong, Hong Kong 
16.  
Efficacy of Chloroquine and Lopinavir/ Ritonavir 
in mild/general novel coronavirus (CoVID-19) 
infections: a prospective, open-label, multicenter 
randomized controlled clinical study 
1.Chloroquine 
2. Lopinavir/ Ritonavir 
- 
The Fifth Affiliated Hospital Sun Yat-Sen 
University 
17.  
A study for the efficacy of hydroxychloroquine 
for mild and moderate COVID-19 infectious 
diseases 
Hydroxychloroquine - 
The Second Affiliated Hospital of Chongqing 
Medical University 
18.  
A prospective, randomized, open-label, parallel 
controlled trial for the preventive effect of 
hydroxychloroquine on medical personnel after 
exposure to COVID-19 
Hydroxychloroquine - Renmin Hospital of Wuhan University 
19.  
The efficacy and safety of carrimycin treatment in 
patients with novel coronavirus infectious disease 
(COVID-19): a multicenter, randomized, open- 
label controlled trial 
Carrimycin - 
Beijing You'an Hospital, Capital Medical 
University 
20.  
A prospective clinical study for recombinant 
human interferon alpha 1b spray in the prevention 
of novel coronavirus (COVID-19) infection in 
highly exposed medical staffs. 
recombinant human interferon 
alpha 1b 
- Chinese PLA General Hospital 
21.  A Pilot Study of Sildenafil in COVID-19 Sildenafil citrate Recruiting 
Department and Institute of Infectious Disease, 
Wuhan, Hubei, China 
22.  
Comparison of Lopinavir/Ritonavir or 
Hydroxychloroquine in Patients With Mild 





Asan Medical Center, University of Ulsan 
College of Medicine, Seoul, Korea, Republic of 
Korea 
23.  
The Efficacy and Safety of Thalidomide 
Combined With Low-dose Hormones in the 





24.  Various Combination of Protease Inhibitors, Oral Not yet Subsai Kongsaengdao, Bangkok, Thailand 
Oseltamivir, Favipiravir, and Chloroquin for 




Chloroquine Prevention of Coronavirus Disease 






Favipiravir Combined With Tocilizumab in the 
Treatment of Corona Virus Disease 2019 
Favipiravir Combined with 
Tocilizumab 
Recruiting 
Anhui Medical University Affiliated First 
Hospital, Hefei, Anhui, China 
Guiqiang Wang, Beijing, Beijing, China 
Peking University First Hospital, Beijing, 
Beijing, China 
27.  









Randomized Controlled Trial of Losartan for 





Hennepin County Medical Center, Minneapolis, 
Minnesota, United States 
M Health Fairview University of Minnesota 
Medical Center, Minneapolis, Minnesota, 
United States 
University of Minnesota, Minneapolis, 
Minnesota, United States 
29.  
Randomized Controlled Trial of Losartan for 





Hennepin County Medical Center, Minneapolis, 
Minnesota, United States 
M Health Fairview University of Minnesota 
Medical Center, Minneapolis, Minnesota, 
United States 
University of Minnesota, Minneapolis, 
Minnesota, United States 
30.  
Evaluation of Ganovo (Danoprevir) Combined 
With Ritonavir in the Treatment of Novel 
Coronavirus Infection 
Ganovo with ritonavir +/-
Interferon 
Recruiting 
The Ninth Hospital of Nanchang 
Nanchang, Jiangxi, China 
31.  
Eculizumab (Soliris) in Covid-19 Infected 
Patients 
Eculizumab Initiated - 
 
  
The table represents a list of selected clinical trials for the amelioration of COVID – 19 specific drugs and vaccines.  
32.  Expanded Access Remdesivir (RDV; GS-5734™) Remdesivir Initiated - 





Post-exposure Prophylaxis for SARS-
Coronavirus-2 
Hydroxychloroquine Recruiting 
University of Minnesota, Minneapolis, 
Minnesota, United States 
35.  
The efficacy and safety of pirfenidone capsules in 
the treatment of severe new coronavirus 
pneumonia (COVID-19) 
Pirfenidone - 
Third Xiangya Hospital of Central South 
University 
 
Table 4: AYUSH recommended medicinal plant extracts for treating COVID-19 
(Ref: AYUSH Ministry of Health Corona Advisory – D.O. No. S. 16030/18/2019 – NAM; dated: 06
th
 March, 2020) 
  
Indian Medicinal Plant Form of 
extract 







Preventive and Prophylactic 
 
Tinospora cordifolia Aqueous Samshamani Vati Ayurveda Samshamani Vati 500gm 
with warm water 
Twice a day for 15 
days 
Chronic fever 
Andrograhis paniculata Aqueous Nilavembu 
kudineer 
Siddha Nilavembu kudineer 60ml 
decoction 
Twice a day for 14 
days 
Fever and cold 






Unani Behidana – 3gm 
Unnab – 5 Nos 
Sapistan – 9 Nos 
Boil these 3 in 250ml water, 
boil it until it remains half 
and filter it 




allergic, smooth muscle 
relaxant, anti-influenza 
activity 
Arsenicum album 30 Tablet Arsenicum album 
30 
Homeopathy - Daily once in empty 
stomach for 3 days 
(Should be repeated 





Symptomatic Management for COVID-19 
 
AYUSH -64 Tablet - Ayurveda - 2 tablets twice a day Respiratory infections 
Agastya Haritaki Powder Agasthya 
Rasayanam 
Ayurveda 5gm in warm water Twice a day Upper respiratory 
infections 
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Table 4 depicts the Indian Medicinal plants and its usage provided by the AYUSH, Government of India as a therapeutic approach for COVID-19. 
Adathodai Manapagu Aqueous Adathodai 
Manapagu 
Siddha - 10ml twice a day Fever 
Bryonia alba Tablet Bryonia Homeopathy - - Reduce lung 
inflammation 
Rhus toxico dendron Tablet Rhus tox Homeopathy - - Viral infections 
Atropa belladonna Tablet Belladonna Homeopathy - - Asthma and chronic 
lung diseases  
Bignonia sempervirens Tablet Gelsemium Homeopathy - - Asthma 
Eupatorium perfoliatum Tablet Eupatorium 
perfoliatum 
Homeopathy - - Respiratory symptoms 
 
Add on Interventions to the Conventional Care 
 
Vishasura kudineer Tablet Poly-herbal 
formulation 
Siddha Decoction 60ml Twice a day Fever 
Kaba sura kudineer Tablet Poly-herbal 
formulation 
Siddha Decoction 60ml Twice a day Fever, cough, sore 
throat, shortness of 
breath 
S.No Plant Source Mechanism of action           Target  Virus Reference 
1. Acacia nilotica Inhibition - HIV-PR Mishra et al. 2014 
2. Allium sativum Proteolytic and 
hemagglutinating activity and 
viral replication 
- SARS Keyaerts et al. 2004 
3. Andrographis 
paniculata 
Suppression NLRP3, capase-1, and IL-
1β  
SARS-COV and likely 
SARS-CoV-2 
Liu et al. 2020 
 
4. Boerhaavia diffusa Inhibition ACE - Prathapan et al. 2013; Khan and 
Kumar 2019 
5. Clerodendrum inerme 
Gaertn 
Inactivation Ribosome SARS-CoV-2 Olivieri et al. 1996 
6. Clitoria ternatea Metalloproteinase inhibitor  ADAM17 - Maity et al. 2012 
7. Coriandrum sativum Inhibition ACE - Pandey et al. 2011 
8. Cynara scolymus  
Cassia occidentalis 
Coscinium fenestratum 
Inhibition ACE - Prathapan et al. 2013; Khan and 
Kumar 2019 
9. Embelia ribes Inhibition ACE - Prathapan et al. 2013; Khan and 
Kumar 2019 
10. Eugenia jambolana Inhibition Protease - Otake et al. 1995 
11. Euphorbia granulata Inhibition - HIV-1 PR Mishra et al. 2014 
 
12. Glycyrrhiza glabra Inhibition of viral replication; 
Modulation of membrane 
fluidity 
 SARS; HIV-1 Akamatsu et al. 1991; Cinatl et al. 
2003; Fiore et al. 2008 
13. Gymnema sylvestre Inhibition of viral DNA 
synthesis 
- - Vimalanathan et al. 2009; Arun et al. 
2014 
14. Hyoscyamus niger Inhibition and Bronchodilator Ca2+ - Gilani et al. 2008 
15. Ocimum 
kilimandscharicum 
Inhibition - HIV-1 Thayil Seema and Thyagarajan 2016 
16. Ocimum sanctum Inhibition - HIV-1 Rege and Chowdhary 2014 
17. Punica granatum Inhibition ACE - Prathapan et al. 2013; Khan and 
Kumar 2019 
18. Salacia oblonga Suppression angiotensin II, AT1 signal - He et al. 2011 
Table 5: List of Indian medicinal herbs which might inhibit the HCoVs and other Viruses 
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19. Sambucus ebulus Inhibition - Enveloped virus Ganjhu et al. 2015 
 
20. Solanum nigrum - - HIV-1 Yu 2004 
21. Sphaeranthus indicus Inhibition - Mouse corona virus and 
Herpes virus 
Galani et al. 2010 
Tiwari and Khosa 2009; 
Vimalanathan et al. 2009 
22. Strobilanthes callosa Blocking - HCoV-NL63 
 
Tsai et al., 2020 
Tsai et al. 2020 
23. Strobilanthes cusia Blocking - HCoV-NL63 Tsai et al., 2020 
Tsai et al. 2020 
24. Vitex negundo Inhibition - HIV-1 NAIR 2012 
25. Vitex trifolia Reduction - SARS-COV Liou et al. 2018 
 
HIV- 1PR: Human Influenza Virus – 1 Protease; SARS: Severe Acute Respiratory Syndrome; SARS-CoV: Severe Acute Respiratory Syndrome – 
Coranavirus; SARS-CoV-2: Severe Acute Respiratory Syndrome – Coranavirus 2; ACE – Angiotensin converting enzyme; HIV‐1: Human Influenza 
Virus – 1; gp120: Envelope Glycoprotein 120; CD4: Cluster of Differentiation; HCoV-NL63: Human coronavirus NL63; RNA: Ribonucleic acid; 
MHV-A59: Mouse Hepatitis Virus –A59; CA2+: Calcium ion; NLRP3: NLR Family Pyrin Domain Containing 3; AT1: Angiotensin 1; HCoV-NL63:  
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Structure and binding of COVID-19 virus to ACE2: 
Fig.1: The above-mentioned figure depicts the structure of the COVID-19 virus. Among the viral 
structure the S protein has a major role in binding of the virus to the host receptor cells. S protein has 
two subunits which are the S1 receptor-binding subunit and S2 the membrane fusion subunit; where 
the earlier one attached itself to the ACE2 receptor of the human host cell and the S2 subunit 
internalises and creates the membrane fusion among the viral subunit and the ACE2 receptors. This 
leads to the release of the viral RNA into the host cell and results into respiratory infection. 
 
Possible mechanism of action of SARS-COV-2 
Fig.2: Depiction of the binding of SARS-COV-2 to its receptor ACE-2. The S1 and S2 subunits are 
subsequently cleaved followed by the shedding of ACE-2 by ADAM 17. This resulting in an 
increased amount of Angiotensin II leading to respiratory distress. Upon binding, the virus fuses with 
the membrane and enters the cell, followed by translation, and replication of the proteins. ORF3a, 
ORF8b,E proteins and the NF-KB pathway activates the inflammasome pathway through various 
means, leading to the activation of cytokine. This results in a cytokine storm, further resulting in 
respiratory distress. 
 
COVID-19 entry into CNS  
Fig.3:  Entry of human Coronavirus in CNS through olfactory bulb upon nasal infection 
which causes inflammation and demyelination. Further it reaches the whole brain via Blood 
Brain Barrier and CSF via Blood- CSF barrier in < 7 days. The possible entry of SARS-CoV-2 
into the Brain and CNS is important to design effective antiviral drugs. Effective drugs that may cross 
Blood Brain Barrier and Blood CSF barrier may be taken in to consideration while designing and this 
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